Log in

Relevant bibliographies by topics / Inc Catapult / Journal articles

To see the other types of publications on this topic, follow the link: Inc Catapult.

Journal articles on the topic 'Inc Catapult'

Author: Grafiati

Published: 26 July 2024

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 39 journal articles for your research on the topic 'Inc Catapult.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Bishko, C. J. "St James's Catapult. The Life and Times of Diego Gelmírez of Santiago de Compostela. By R. A. Fletcher. Pp. xii + 341 inc. 2 maps. Oxford: Clarendon Press, 1984. £28." Journal of Ecclesiastical History 36, no. 4 (1985): 650–52. http://dx.doi.org/10.1017/s0022046900044067.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Woyach, Jennifer A., Amy S. Ruppert, Nyla A. Heerema, et al. "Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy." Blood 138, Supplement 1 (2021): 639. http://dx.doi.org/10.1182/blood-2021-153146.

Full text

Abstract:

Abstract Introduction: Alliance for Clinical Trials in Oncology A041202 is a NCI National Clinical Trials Network phase 3 study (NCT01886872) comparing BR (Arm 1) with ibrutinib (Arm 2) and the combination of ibrutinib plus rituximab (Arm 3) to determine whether ibrutinib-containing regimens are superior to chemoimmunotherapy (CIT) in terms of progression-free survival (PFS), and whether rituximab adds benefit to ibrutinib therapy. Initial results showed that ibrutinib-containing regimens had superior PFS to CIT, and that rituximab added to ibrutinib did not improve PFS over ibrutinib alone. P

APA, Harvard, Vancouver, ISO, and other styles

3

Bannerji, Rajat, John N. Allan, Jon E. Arnason, et al. "Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)." Blood 134, Supplement_1 (2019): 762. http://dx.doi.org/10.1182/blood-2019-122451.

Full text

Abstract:

Background REGN1979 is an anti-CD20 x anti-CD3 bispecific IgG4 antibody (Ab) modified to reduce Fc binding. Engaging both targets results in CD20-specific, local T-cell activation and cytotoxicity, a mechanism of action distinct from standard anti-CD20 Abs. Dose escalation is complete and a recommended Ph 2 dose has been determined. We report Ph 1 safety and efficacy results of REGN1979 in patients (pts) with R/R B-NHL previously treated with anti-CD20 Abs, including pts with progressive disease after anti-CD19 CAR T-cell (CAR T) therapy. Methods Primary objectives are to determine safety, tol

APA, Harvard, Vancouver, ISO, and other styles

4

Vartanov, Alexander R., Stacey M. Fernandes, Winnie I. Nguy, et al. "High Sensitivity NGS Analysis of MRD in CLL Patients Prospectively Treated with Ibrutinib Plus FCR (iFCR)." Blood 134, Supplement_1 (2019): 4291. http://dx.doi.org/10.1182/blood-2019-124305.

Full text

Abstract:

Background Studies from the chemoimmunotherapy (CIT) era and more recently with venetoclax have demonstrated the correlation between minimal residual disease (MRD) response measured by at least four-color flow cytometry (FC), and progression free (PFS) and overall survival (OS) in CLL. Despite high overall (ORR) and complete (CR) response rates observed with fludarabine-based combination CIT, the ability to achieve sustained undetectable MRD (uMRD) remission is lacking for the majority of patients treated with these regimens. We have previously reported on the promising combination of ibrutini

APA, Harvard, Vancouver, ISO, and other styles

5

Spangler, Rhys, Timo Rantalainen, Paul Gastin, and Daniel Wundersitz. "Inertial Sensors are a Valid Tool to Detect and Consistently Quantify Jumping." International Journal of Sports Medicine 39, no. 10 (2018): 802–8. http://dx.doi.org/10.1055/s-0044-100793.

Full text

Abstract:

AbstractConsidering the large and repetitive loads associated with jumping in team sports, automatic detection and quantification of jumping may show promise in reducing injury risks. The aim of this study was to validate commercially available inertial-movement analysis software to detect and quantify jumping in team sports. In addition, the test-retest reliability of the software to quantify jumping was assessed. Seventy-six healthy male participants completed a team sport circuit six times containing seven common movements (including three countermovement and two single-leg jumps) whilst we

APA, Harvard, Vancouver, ISO, and other styles

6

Naeem, Aishath S., Winnie I. Nguy, Svitlana Tyekucheva, et al. "LOXO-305: Targeting C481S Bruton Tyrosine Kinase in Patients with Ibrutinib-Resistant CLL." Blood 134, Supplement_1 (2019): 478. http://dx.doi.org/10.1182/blood-2019-124362.

Full text

Abstract:

Clinical success with the targeted Bruton Tyrosine Kinase (BTK) inhibitors ibrutinib and acalabrutinib has greatly improved the outcome of patients with relapsed chronic lymphocytic leukemia (CLL). However toxic side effects and acquired resistance due to C481S mutations in BTK remain an issue and the prognosis of those developing resistance is poor. Hence better therapeutic options are needed for these patients. Here we characterize a next generation highly selective reversible BTK inhibitor, LOXO-305, and describe its effectiveness in vitro in treatment naïve CLL patients and in those with C

APA, Harvard, Vancouver, ISO, and other styles

7

Mato, Anthony R., Kavita Sail, Maryam Sarraf Yazdy, et al. "Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies." Blood 134, Supplement_1 (2019): 1756. http://dx.doi.org/10.1182/blood-2019-124600.

Full text

Abstract:

BACKGROUND Novel agents have changed the treatment landscape in chronic lymphocytic leukemia (CLL), however little has been reported about real-world treatment sequence patterns and associated outcomes post-introduction of novel agents. Studies have demonstrated that venetoclax is effective for patients (pts) who have discontinued ibrutinib, however treatments and outcomes post-venetoclax discontinuation remain unclear. The objective of this study was to examine real-world treatment sequence patterns post-introduction of novel agents and specifically understand treatment sequencing following v

APA, Harvard, Vancouver, ISO, and other styles

8

Shadman, Mazyar, Kavita Sail, Beenish S. Manzoor, et al. "Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study." Blood 134, Supplement_1 (2019): 3048. http://dx.doi.org/10.1182/blood-2019-131401.

Full text

Abstract:

BACKGROUND The recent approval of novel agents (NAs) has changed the treatment landscape in chronic lymphocytic leukemia (CLL), however, there remains uncertainty regarding treatment discontinuation patterns in real-world (RW) settings. This study assessed patterns of and reasons for discontinuation for patients (pts) treated with chemotherapy/chemoimmunotherapy (CT/CIT) and NAs in first (1L) and second (2L) lines of therapy in CLL. METHODS The CLL Collaborative Study of Real-World Evidence (CORE) study is a retrospective, multicenter, observational study. Adult CLL patients (pts) were include

APA, Harvard, Vancouver, ISO, and other styles

9

Lampson, Benjamin L., Svitlana Tyekucheva, Conner J. Shaughnessy, Annette S. Kim, and Jennifer R. Brown. "Incidence of Germline ATM Variants in a Consecutive Clinical Cohort of CLL Patients." Blood 134, Supplement_1 (2019): 1731. http://dx.doi.org/10.1182/blood-2019-127180.

Full text

Abstract:

Background The pathogenesis of chronic lymphocytic leukemia (CLL) remains unknown, but first-degree relatives of affected patients (pts) have a 3-to-8-fold increased risk of developing CLL, suggesting an inherited component. Previously, we performed an exome-wide comparison of rare germline variants (vts) among CLL pts compared to controls and identified a 1.8X increased risk of any rare germline ATM vt in CLL pts. Certain vts had much higher relative risk; for example, ATM p.L2307F was associated with a 10X increased risk of CLL (Tiao Leukemia 2017). ATM p.F858L and p.P1054R also imparted a 2

APA, Harvard, Vancouver, ISO, and other styles

10

Brown, Jennifer R., Matthew S. Davids, Julie E. Chang, et al. "Outcomes of Ibrutinib (Ibr) Therapy in Ibr-Naïve Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Progressing after Venetoclax (Ven)." Blood 134, Supplement_1 (2019): 4320. http://dx.doi.org/10.1182/blood-2019-123665.

Full text

Abstract:

Introduction: The approval of several new, targeted agents has been transformative in the treatment of CLL. Prospective clinical trial data support the use of Ven after Ibr in CLL (Jones JA et al. Lancet Oncol 2018); however, limited data are available on the inverse sequencing of these agents (Mato AR et al. Br J Haematol 2018; Anderson M et al. Blood 2017). Given the recent FDA approval of Ven + obinutuzumab in first-line (1L) CLL, an upsurge in Ibr-naïve pts needing therapy post-Ven is likely; characterizing this sequencing is of the upmost importance. Here we present a US multicentre, retr

APA, Harvard, Vancouver, ISO, and other styles

11

Liu, Vivian M., Romain Guièze, Daniel Rosebrock, et al. "MCL-1 and PKA/AMPK Axis Fuel Venetoclax Resistance in Lymphoid Cancers." Blood 134, Supplement_1 (2019): 1284. http://dx.doi.org/10.1182/blood-2019-131336.

Full text

Abstract:

Venetoclax, the first approved BH3 mimetic targeting BCL2, demonstrates high response rate in chronic lymphocytic leukemia (CLL) but resistant cases are emerging. Aside from BCL2 mutations affecting venetoclax binding, multiple lines of mounting evidence suggest a role for non-mutational mechanisms underlying resistance to this drug. By applying both CRISPR-Cas9 knock-out and ORF overexpression screens in the lymphoma cell line OCI-Ly1, we previously reported the identification of MCL-1 overexpression and of the AMPK/PKA signaling axis in altering energy metabolism underlying venetoclax resist

APA, Harvard, Vancouver, ISO, and other styles

12

Allan, John N., Krish Patel, Anthony R. Mato, et al. "Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell Malignancies." Blood 134, Supplement_1 (2019): 3041. http://dx.doi.org/10.1182/blood-2019-126286.

Full text

Abstract:

Background: Vecabrutinib is a selective, reversible, noncovalent BTK inhibitor (BTKi) with potent in vitro inhibitory activity against both wild type and C481S-mutated BTK, the most common mutation detected in patients (pts) with CLL relapsing on treatment with covalent BTKi (cBTKi). Methods: This is an open-label, modified 3+3 dose-escalation, cohort expansion phase 1b/2 trial to evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD), maximum tolerated dose (MTD) and antitumor activity of oral vecabrutinib in adult pts with relapsed/refractory advanced B-cell malignancies who must have

APA, Harvard, Vancouver, ISO, and other styles

13

Mato, Anthony R., John M. Pagel, Catherine C. Coombs, et al. "Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study." Blood 138, Supplement 1 (2021): 391. http://dx.doi.org/10.1182/blood-2021-147599.

Full text

Abstract:

Abstract Background: Covalent BTK inhibitors (BTKi) have transformed the management of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), but these treatments are not curative and many patients (pts) will require additional treatment. Covalent BTKi share pharmacologic liabilities (e.g. low oral bioavailability, short half-life) that collectively may lead to suboptimal BTK target coverage, for example in rapidly proliferating tumors with high BTK protein turnover such as accelerating CLL/SLL, ultimately manifesting as acquired resistance in some pts. To address these limitations

APA, Harvard, Vancouver, ISO, and other styles

14

Furman, Richard R., William G. Wierda, Anna Schuh, et al. "Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study." Blood 134, Supplement_1 (2019): 3039. http://dx.doi.org/10.1182/blood-2019-128706.

Full text

Abstract:

Background: Targeted inhibition of Bruton tyrosine kinase (BTK) has improved clinical outcomes for patients with chronic lymphocytic leukemia (CLL). Acalabrutinib is a highly selective, covalent BTK inhibitor. A recently completed phase 3 trial showed acalabrutinib improved progression-free survival (PFS) vs idelalisib or bendamustine + rituximab in relapsed/refractory (R/R) CLL patients (ASCEND: Ghia et al. EHA 2019;273259:LB2606). This is an updated analysis with extended follow-up of a phase 1-2 multicenter study (NCT02029443) in patients with R/R CLL/small lymphocytic lymphoma (SLL), to de

APA, Harvard, Vancouver, ISO, and other styles

15

Zheng, Dandan, Kavita Sail, Lindsey E. Roeker, et al. "Venetoclax Effectiveness, Safety, and Treatment Patterns in Chronic Lymphocytic Leukemia Patients: Results from the CLL Collaborative Study of Real-World Evidence (CORE)." Blood 136, Supplement 1 (2020): 19–22. http://dx.doi.org/10.1182/blood-2020-134676.

Full text

Abstract:

Introduction: Venetoclax has demonstrated deep responses and sustained progression-free survival and is well tolerated in patients (pts) with previously untreated or relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) in clinical trials. Some early studies provided initial insight of venetoclax utilization in the real-world (RW), but RW evidence focusing on venetoclax effectiveness and safety is still limited. This study assessed venetoclax effectiveness, safety, and treatment patterns in CLL pts treated in clinical practice. Methods: The CLL Collaborati

APA, Harvard, Vancouver, ISO, and other styles

16

N., Sharadha, and V. Manickavasagam Prof. "IND AS India's Accounting Standards Converged with the IFRS IND AS Adoption and Applicability for Indian Companies." International Journal of Trend in Scientific Research and Development 2, no. 2 (2018): 628–32. https://doi.org/10.31142/ijtsrd9428.

Full text

Abstract:

India made a commitment towards the convergence of Indian accounting standards with IFRS at theG20 summit in 2009. In line with this, the Ministry of Corporate Affairs, Government of India MCA previously issued a roadmap for implementation of Indian Accounting Standards Ind AS convergedwith International Financial Reporting Standards IFRS beginning April 2011. However, this planwas suspended due to unresolved tax and other issues.In the presentation of the Union Budget 2014-15, the Honorable Minister for Finance, CorporateAffairs and Information and Broadcasting proposed the adoption of Ind AS

APA, Harvard, Vancouver, ISO, and other styles

17

Chahal, Amandeep Kaur, Jolene Ziyuan Lim, Jing-Wen Pan, and Pui Wah Kong. "Inter-Unit Consistency and Validity of 10-Hz GNSS Units in Straight-Line Sprint Running." Sensors 22, no. 5 (2022): 1888. http://dx.doi.org/10.3390/s22051888.

Full text

Abstract:

The present study aimed to investigate the inter-unit consistency and validity of multiple 10-Hz Catapult Global Navigation Satellite System (GNSS) units in measuring straight-line sprint distances and speeds. A total of 13 participants performed one 45.72-m linear sprint at maximum effort while wearing all eight GNSS units at once. Total run distance and peak speed recorded using GNSS units during the sprint duration were extracted for analysis. Sprint time and peak speed were also obtained from video recordings as reference values. Inter-unit consistency was assessed using intraclass correla

APA, Harvard, Vancouver, ISO, and other styles

18

Hillmen, Peter, Jennifer R. Brown, John C. Byrd, et al. "Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)." Blood 134, Supplement_1 (2019): 4307. http://dx.doi.org/10.1182/blood-2019-124213.

Full text

Abstract:

Background: Bruton tyrosine kinase (BTK) plays a critical role in B-cell receptor signaling, which mediates B-cell proliferation, migration, and adhesion. Inhibition of BTK has emerged as a strategy for targeting B-cell malignancies including CLL/SLL. Zanubrutinib (BGB-3111) is an investigational, next-generation BTK inhibitor that was designed to maximize BTK occupancy and minimize off-target inhibition of TEC- and EGFR-family kinases. Increased specificity may minimize toxicities reported with ibrutinib potentially due to off-target inhibition such as diarrhea, thrombocytopenia, bleeding, at

APA, Harvard, Vancouver, ISO, and other styles

19

Mato, Anthony R., Ian W. Flinn, John M. Pagel, et al. "Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor." Blood 134, Supplement_1 (2019): 501. http://dx.doi.org/10.1182/blood-2019-127509.

Full text

Abstract:

Introduction: Bruton Tyrosine Kinase inhibitors (BTKis) have transformed the treatment of patients with chronic lymphocytic leukemia (CLL) and other B-cell malignancies by inducing durable responses, improving quality of life and prolonging overall survival. Prolonged use of BTKi in the real-world setting is limited by toxicity and acquired resistance. Discontinuation rates for BTKis may be as high as 40% in relapsed/refractory CLL, with BTK C481-mediated resistance evident in many progressing patients. Alternative therapies such as venetoclax are associated with on-target (BCL2) acquired resi

APA, Harvard, Vancouver, ISO, and other styles

20

Lancet, Jeffrey E., Farhad Ravandi, Ellen K. Ritchie, et al. "Baseline Predictors of Mortality in Patients with Relapsed or Refractory Acute Myeloid Leukemia Treated with Vosaroxin Plus Cytarabine or Placebo Plus Cytarabine in the Phase 3 VALOR Study." Blood 126, no. 23 (2015): 2560. http://dx.doi.org/10.1182/blood.v126.23.2560.2560.

Full text

Abstract:

Abstract Introduction: The rate of early mortality in patients treated for acute myeloid leukemia (AML) reflects a balance of efficacy and safety outcomes. In the randomized phase 3 VALOR trial in patients with first relapsed or refractory AML, rates of 30-day (7.9% vs 6.6%, respectively) and 60-day (19.7% vs 19.4%, respectively) mortality were comparable between vosaroxin plus cytarabine and placebo plus cytarabine arms. The treatment-related mortality (TRM) score is a prognostic scoring system to predict risk of 30-day mortality with intensive treatment protocols in patients with newly diagn

APA, Harvard, Vancouver, ISO, and other styles

21

Bachireddy, Pavan, Christina Ennis, Vinhkhang N. Nguyen, et al. "Distinct Evolutionary Patterns in Chronic Lymphocytic Leukemia (CLL) during Resistance to Graft-Versus-Leukemia (GvL)." Blood 134, Supplement_1 (2019): 516. http://dx.doi.org/10.1182/blood-2019-129520.

Full text

Abstract:

The factors mediating GvL resistance following allogeneic stem cell transplant (SCT) in lymphoid malignancies remain incompletely characterized. Because cell-intrinsic features shape chemotherapeutic relapse, we hypothesized that they also shape GvL outcomes by influencing evolutionary trajectories of CLL relapse after reduced intensity conditioning SCT (RIC). We identified 9 heavily pre-treated patients (pts) (range: 1-5 therapies, median: 3) with various times to CLL relapse after RIC (range: 83-1825 days), of which 8 had at least partial responses before relapse. To define evolutionary traj

APA, Harvard, Vancouver, ISO, and other styles

22

Tam, Constantine S., Ian W. Flinn, Alessandra Tedeschi, et al. "Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and del(17p): Arm D of the SEQUOIA (BGB-3111-304) Trial." Blood 136, Supplement 1 (2020): 24–25. http://dx.doi.org/10.1182/blood-2020-134179.

Full text

Abstract:

Background: Zanubrutinib is a highly selective, next-generation Bruton tyrosine kinase (BTK) inhibitor designed to maximize BTK occupancy and minimize off-target effects. Zanubrutinib has been associated with improved specificity and durable clinical responses in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; Tam, Blood 2019;134:851-9). Early clinical data from Arm C of the SEQUOIA trial suggested that zanubrutinib was active and well-tolerated in treatment-naïve (TN) CLL/SLL patients with the high-risk characteristic deletion of chromosome 17p13.1 [del(17p)] (

APA, Harvard, Vancouver, ISO, and other styles

23

Brown, Jennifer R., Barbara F. Eichhorst, Paolo Ghia, et al. "A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with Investigator's Choice of Chemoimmunotherapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) without Del(17p) or TP53 Mutation." Blood 134, Supplement_1 (2019): 4318. http://dx.doi.org/10.1182/blood-2019-123057.

Full text

Abstract:

Background: Chronic lymphocytic leukemia (CLL) is the most prevalent type of adult leukemia. In many countries, chemoimmunotherapy (CIT) remains the standard of care for frontline treatment of patients without high-risk cytogenetics. Although in most patients the disease responds initially, CIT can be associated with early and late toxicity and limited progression-free survival (PFS), requiring subsequent treatment. Novel chemotherapy-free targeted agents are highly effective but need to be taken continuously, which is associated with development of resistance clones and considerable medical a

APA, Harvard, Vancouver, ISO, and other styles

24

Crombie, Jennifer L., Svitlana Tyekucheva, Alexandra Savell, et al. "A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL." Blood 134, Supplement_1 (2019): 1763. http://dx.doi.org/10.1182/blood-2019-127343.

Full text

Abstract:

Introduction: Duvelisib (DUV), an oral inhibitor of PI3K-δ/γ, and venetoclax (VEN), an oral inhibitor of BCL-2, are both approved for relapsed/refractory (R/R) CLL. We previously found that PI3K-δ inhibition sensitizes CLL cells to ex vivo BCL-2 inhibition (Davids et al., Blood, 2012). We hypothesized that DUV plus VEN would lead to deep remissions that allow for an all oral, time-limited therapy. Here, we report for the first time on a phase I study of DUV plus VEN for patients (pts) with R/R CLL/SLL. Methods: This is an investigator-initiated phase I trial with primary endpoints: DLTs, MTD,

APA, Harvard, Vancouver, ISO, and other styles

25

Merryman, Reid W., Robert A. Redd, Eleanor Taranto, et al. "Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma." Blood 136, Supplement 1 (2020): 22–23. http://dx.doi.org/10.1182/blood-2020-140965.

Full text

Abstract:

Background: While autologous stem cell transplantation (ASCT) can be curative for patients (pts) with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), relapse remains common. With the emergence of novel effective therapies, it is even more important to identify pts at high risk of treatment failure who may not benefit from ASCT, and pts with impending post-ASCT relapse who may be candidates for pre-emptive interventions. We assembled cohorts of DLBCL pts who underwent ASCT and had apheresis stem cell (ASC) samples or serially collected post-ASCT peripheral blood mononuclear cell (

APA, Harvard, Vancouver, ISO, and other styles

26

Burke, Kathleen, Barrett Nuttall, Daniel L. Karl, et al. "Novel Mechanisms of Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia By Whole Genome Methylome Sequencing." Blood 138, Supplement 1 (2021): 4361. http://dx.doi.org/10.1182/blood-2021-147113.

Full text

Abstract:

Abstract Background: Bruton's tyrosine kinase (BTK) inhibition is a key component in B-cell receptor signaling and is one of the most prominent therapeutic targets in hematologic malignancies. Acalabrutinib is a highly selective, covalent, potent next-generation inhibitor of BTK (Barf et al, 2017) and is approved for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia (CLL). However, a small subset of patients develop resistance to acalabrutinib over time. While the major mechanism of resistance to covalent BTK inhibitors is explained by acquired mutations in BTK-Cys481 and

APA, Harvard, Vancouver, ISO, and other styles

27

Davids, Matthew S., Kirsten Fischer, Sandra Robrecht, et al. "ReVenG: A Phase 2 Study of Venetoclax Plus Obinutuzumab Retreatment in Patients with Relapsed Chronic Lymphocytic Leukemia." Blood 138, Supplement 1 (2021): 2634. http://dx.doi.org/10.1182/blood-2021-153033.

Full text

Abstract:

Abstract Background: The combination of venetoclax (Ven), a selective oral B-cell lymphoma-2 inhibitor, and obinutuzumab (Obi), a type II anti-CD20 monoclonal antibody, is approved as a 12-cycle fixed duration treatment for adult patients (pts) with previously untreated chronic lymphocytic leukemia (CLL). In the CLL14 study, pts with CLL and coexisting conditions treated with Ven-Obi achieved high rates of undetectable minimal residual disease (uMRD), translating into a 4-year progression free survival (PFS) of 74%. Despite these favorable results, disease relapse may occur after cessation of

APA, Harvard, Vancouver, ISO, and other styles

28

Lampson, Benjamin L., Svitlana Tyekucheva, Jennifer L. Crombie, et al. "Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)." Blood 134, Supplement_1 (2019): 32. http://dx.doi.org/10.1182/blood-2019-127506.

Full text

Abstract:

Backgound Venetoclax (V) plus obinutuzumab (O) regimen is active as frontline CLL treatment; a little over half of patients (pts) will achieve undetectable minimal residual disease in the bone marrow (BM-uMRD) with one year of time-limited therapy (Fischer et al. NEJM 2019). Novel strategies may further augment the efficacy of VO. Ibrutinib was previously combined with VO, but relatively high rates of infusion reactions and neutropenia were observed, as were the characteristic toxicities of ibrutinib including diarrhea and bruising (Rogers et al. Blood 2018). Acalabrutinib (A), a more selectiv

APA, Harvard, Vancouver, ISO, and other styles

29

Davids, Matthew S., Danielle M. Brander, Svitlana Tyekucheva, et al. "Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia." Blood 138, Supplement 1 (2021): 640. http://dx.doi.org/10.1182/blood-2021-146624.

Full text

Abstract:

Abstract Introduction FCR remains the only therapy other than allo transplant proven to provide a significant chance of functional cure with very long term follow-up for young, fit patients with mutated IGHV CLL. Given the excellent efficacy and tolerability of ibrutinib in a broad population of young, fit CLL patients, we designed the frontline iFCR study to investigate whether time-limited novel agent plus chemoimmunotherapy could provide durable remission for CLL patients irrespective of IGHV status. We previously reported that with a median follow-up of 16.5 months, the rate of CR with bon

APA, Harvard, Vancouver, ISO, and other styles

30

Ball, William J. "Book Reviews : Beyond the Home Page Book Review Essay on Guides to Advanced Content Creation for the Web Introducing Microsoft FrontPage97. Kerry A. Lehto and W. Brett Polonsky. Redmond, WA: Microsoft Press, 1997. 384 pp., $24.99. Microsoft FrontPage97 Step by Step. Catapult Inc. Redmond, WA: Microsoft Press, 1997. 286 pp., $29.99. Web Scripting Secret Weapons. Scott Walker. Indianapolis, IN: Que Corp., 1997. 380 pp., $39.99. Special Edition Using JavaScript. Mark C. Reynolds. Indianapolis, IN: Que Corp., 1997. 831 pp., $49.99. VBScript by Example. Jerry Honeycutt. Indianapolis, IN: Que Corp., 1997. 355 pp., $34.99. Building VRML Worlds. Ed Tittle, Charlie Scott, Paul Wolfe, and Claire Sanders. Berkeley, CA: Osborne/McGraw Hill, 1997. 381 pp., $39.95." Social Science Computer Review 15, no. 4 (1997): 446–50. http://dx.doi.org/10.1177/089443939701500411.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Seymour, John F., John C. Byrd, Peter Hillmen, et al. "Characterization of Bruton Tyrosine Kinase Inhibitor (BTKi)-Related Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)." Blood 138, Supplement 1 (2021): 3721. http://dx.doi.org/10.1182/blood-2021-146228.

Full text

Abstract:

Abstract Background: The phase 3 head-to-head trial of acalabrutinib (acala) vs ibrutinib (ibr) (NCT02477696) demonstrated noninferior efficacy and improved tolerability with acala in previously treated CLL (Byrd J Clin Oncol 2021). We now report additional data to further characterize BTKi-related adverse events (AEs) and the safety profile of acala and ibr, including measures of AE burden that account for frequency, duration, and drug exposure, which are not captured by incidence alone. Methods: Patients (pts) received oral acala 100 mg BID or ibr 420 mg QD until disease progression or unacc

APA, Harvard, Vancouver, ISO, and other styles

32

Tedeschi, Alessandra, Emmanuelle Ferrant, Ian W. Flinn, et al. "Zanubrutinib in Combination with Venetoclax for Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Early Results from Arm D of the SEQUOIA (BGB-3111-304) Trial." Blood 138, Supplement 1 (2021): 67. http://dx.doi.org/10.1182/blood-2021-144336.

Full text

Abstract:

Abstract Background: Zanubrutinib is a selective next-generation Bruton tyrosine kinase (BTK) inhibitor designed to have high specificity for BTK and minimize off-target effects (J Med Chem 2019;62:7923-40). Data from several phase 2 CLL trials assessing BCL-2 and BTK inhibitor combination treatment suggested that undetectable minimal residual disease (uMRD)-driven fixed-duration combination treatment was tolerable and enabled durable responses after treatment discontinuation (JAMA Oncol 2021;1649.; EHA 2021 S147). However, a limited number of patients with the high-risk feature, deletion of c

APA, Harvard, Vancouver, ISO, and other styles

33

Brown, Jennifer R., Tadeusz Robak, Paolo Ghia, et al. "Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial." Blood 136, Supplement 1 (2020): 11–12. http://dx.doi.org/10.1182/blood-2020-134280.

Full text

Abstract:

Background: Patients (pts) with CLL/SLL whose tumor exhibits the deletion of chromosome 17p13.1 [del(17p)] have an unfavorable prognosis and respond poorly to standard chemoimmunotherapy. Zanubrutinib (BGB-3111) is an investigational, next-generation Bruton tyrosine kinase (BTK) inhibitor. In the ASPEN study of pts with Waldenström macroglobulinemia, zanubrutinib was associated with important safety advantages compared to ibrutinib, especially regarding cardiovascular toxicity (Blood; in press). The initial results from Arm C of the SEQUOIA (BGB-3111-304) trial of zanubrutinib in a large cohor

APA, Harvard, Vancouver, ISO, and other styles

34

Tam, Constantine S., Krzysztof Giannopoulos, Wojciech Jurczak, et al. "SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)." Blood 138, Supplement 1 (2021): 396. http://dx.doi.org/10.1182/blood-2021-148457.

Full text

Abstract:

Abstract Background: Zanubrutinib (zanu) is a selective next-generation Bruton tyrosine kinase (BTK) inhibitor designed to have high specificity for BTK and minimize off-target effects (Guo, J Med Chem 2019;62:7923-40). In a phase 1/2 study, zanu demonstrated complete and sustained BTK occupancy in both peripheral blood mononuclear cells and lymph nodes and was associated with durable clinical responses in patients (pts) with CLL/SLL (Tam, Blood 2019;134:851-9). Here, we present interim results for the phase 3 SEQUOIA (BGB-3111-304; NCT03336333) trial, which evaluated the efficacy and safety o

APA, Harvard, Vancouver, ISO, and other styles

35

Makar, Piotr, Ana Filipa Silva, Rafael Oliveira, et al. "Assessing the agreement between a global navigation satellite system and an optical-tracking system for measuring total, high-speed running, and sprint distances in official soccer matches." Science Progress 106, no. 3 (2023). http://dx.doi.org/10.1177/00368504231187501.

Full text

Abstract:

This study aimed to compare the agreement of total distance (TD), high-speed running (HSR) distance, and sprint distance during 16 official soccer matches between a global navigation satellite system (GNSS) and an optical-tracking system. A total of 24 male soccer players, who are actively participating in the Polish Ekstraklasa professional league, were included in the analysis conducted during official competitions. The players were systematically monitored using Catapult GNSS (10-Hz, S7) and Tracab optical-tracking system (25-Hz, ChyronHego). TD, HSR distance, sprint distance, HSR count (HS

APA, Harvard, Vancouver, ISO, and other styles

36

Watts, Sophie P., Martyn J. Binnie, Paul SR Goods, Matthew M. Doyle, Jamie Hewlett, and Peter Peeling. "Garmin wearable device offers reliable alternative for on-water stroke rate and velocity measurement in rowing." Proceedings of the Institution of Mechanical Engineers, Part P: Journal of Sports Engineering and Technology, May 18, 2022, 175433712210993. http://dx.doi.org/10.1177/17543371221099364.

Full text

Abstract:

Performance tracking devices in the form of wrist-worn watches are common in rowing; however, the accuracy of relevant output variables (i.e. stroke rate [SR] and velocity) during on-water training is unknown. To assess the quality of wrist-watch data output, 16 rowing athletes recorded 118 on-water rowing sessions using a Garmin Forerunner 735XT, which was compared to a Catapult Optimeye R4 tracking device. Garmin recording function was set to ‘Every Second’ ( N = 68 sessions) or ‘Smart’ ( N = 50 sessions). Catapult velocity was calculated as the average velocity per stroke, while a 15 s velo

APA, Harvard, Vancouver, ISO, and other styles

37

Kenawy, A., MY Khanji, M. Chirvasa, et al. "Application of a machine learning contouring tool for the evaluation of left ventricular strain in clinical practice." European Heart Journal - Cardiovascular Imaging 22, Supplement_1 (2021). http://dx.doi.org/10.1093/ehjci/jeaa356.259.

Full text

Abstract:

Abstract Funding Acknowledgements Type of funding sources: Private grant(s) and/or Sponsorship. Main funding source(s): AK has been funded by the Egyptian cultural centre and educational bureau of the Egyptian embassy in London and the Ministry of higher education in Egypt. SEP acknowledges support from the “SmartHeart” EPSRC programme grant (www.nihr.ac.uk; EP/P001009/1) and the London Medical Imaging and AI Centre for Value-Based Healthcare. This new centre is one of the UK Centres supported by a £50m investment from the Data to Early Diagnosis and Precision Medicine strand of the government

APA, Harvard, Vancouver, ISO, and other styles

38

Fucheng Luo. "Multi-Objective Optimization and Intelligent Algorithm Study for 1.5mw Doubly Fed Wind Turbine Blades." Membrane Technology, January 23, 2025, 287–95. https://doi.org/10.52710/mt.247.

Full text

Abstract:

Background: The demand for renewable energy has catapulted wind power to the forefront of sustainable energy options. Designing wind turbine blades is a multi-objective optimization problem with conflicting objectives. Optimization methods such as the weighted sum or the goal programming method fail in this context of conflicting objectives: minimum weight, cost, and strength. The study discusses the integration of artificial intelligence algorithms with conventional design approaches for optimal blades of a 1.5MW DFIG wind turbine. Advanced computational methods are used to integrate aerodyna

APA, Harvard, Vancouver, ISO, and other styles

39

Sexton-Finck, Larissa. "Violence Reframed: Constructing Subjugated Individuals as Agents, Not Images, through Screen Narratives." M/C Journal 23, no. 2 (2020). http://dx.doi.org/10.5204/mcj.1623.

Full text

Abstract:

What creative techniques of resistance are available to a female filmmaker when she is the victim of a violent event and filmed at her most vulnerable? This article uses an autoethnographic lens to discuss my experience of a serious car crash my family and I were inadvertently involved in due to police negligence and a criminal act. Employing Creative Analytical Practice (CAP) ethnography, a reflexive form of research which recognises that the creative process, producer and product are “deeply intertwined” (Richardson, “Writing: A Method” 930), I investigate how the crash’s violent affects cri

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!